Document Detail


Proton pump inhibitor, clarithromycin and either amoxycillin or nitroimidazole: a meta-analysis of eradication of Helicobacter pylori.
MedLine Citation:
PMID:  11012477     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
AIM: To perform a meta-analysis of studies comparing twice daily, one-week triple therapy with a proton pump inhibitor, clarithromycin (C) and amoxycillin (A) (PCA) vs. those using proton pump inhibitor, clarithromycin and a nitroimidazole (N) (PCN) for H. pylori eradication. REVIEW METHODS: Selection criteria: Comparative randomized trials of PCA vs. PCN were included. Data sources: PubMed database and abstracts from congresses until September 1999. Statistics: Meta-analysis was performed combining the Odds Ratios (OR) of the individual studies in a global OR (Peto method) both on an intention-to-treat (ITT) and on a per protocol (PP) basis. RESULTS: Twenty-two studies fulfilled the inclusion criteria. Eighteen studies reported ITT and 20 PP analysis. Mean H. pylori eradication rates were 81% (95% CI: 79-83%) ITT, and 84% (82-86%) PP with PCA, and 81% (78-83%) ITT and 84% (82-86%) PP with PCN; the odds ratio for the effect of PCA vs. PCN was 1 (0.83-1.22) on an ITT, and 0.98 (0.8-1.2) on a PP basis. Subanalysis showed that mean H. pylori eradication efficacy with PC(250 b.d.)A was 81% (78-85%) ITT, vs. 86% (83-89%) with PC(250 b.d.)N. The odds ratio for this comparison was 0.68 (0.48-0.98). Finally, when comparing PC(500 b.d. )A against PC(250 b.d.)N ITT cure rates were 77% (74-80%), and 75% (72-78%) with an odds ratio of 1.18 (0.93-1.5). CONCLUSION: Overall, one-week combination regimens of PCA and PCN present similar H. pylori eradication efficacy. Nevertheless, the PCN regimen obtains significantly better results when using low doses of C (250 mg b.d.).
Authors:
J P Gisbert; L González; X Calvet; N García; T López; M Roqué; R Gabriel; J M Pajares
Related Documents :
6831537 - Development of the capillary system in the neurohypophysis of the rat.
16961437 - Intrinsic fluorescence polarization of amniotic fluid: ii. toward a noninvasive method ...
7124867 - Changes in placental ultrasonic appearance. i. incidence of grade iii changes in the pl...
803787 - Fetal maturity: biochemical analyses of amniotic fluid.
1109267 - A syndrome of multiple congenital anomalies associated with teratogenic exposure.
1199407 - Ultrastructural studies on diphyllobothrium ditremum and d. dendriticum (cestoda, pseud...
Publication Detail:
Type:  Clinical Trial; Journal Article; Meta-Analysis    
Journal Detail:
Title:  Alimentary pharmacology & therapeutics     Volume:  14     ISSN:  0269-2813     ISO Abbreviation:  Aliment. Pharmacol. Ther.     Publication Date:  2000 Oct 
Date Detail:
Created Date:  2000-11-16     Completed Date:  2000-11-16     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  8707234     Medline TA:  Aliment Pharmacol Ther     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  1319-28     Citation Subset:  IM    
Affiliation:
Department of Gastroenterology, University Hospital of La Princesa, Madrid, Spain. gisbert@meditex.es
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amoxicillin / therapeutic use*
Anti-Bacterial Agents / therapeutic use*
Clarithromycin / therapeutic use*
Enzyme Inhibitors / therapeutic use*
Helicobacter Infections / drug therapy*,  microbiology
Helicobacter pylori*
Humans
Nitroimidazoles / therapeutic use*
Penicillins / therapeutic use*
Proton Pumps / antagonists & inhibitors*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Enzyme Inhibitors; 0/Nitroimidazoles; 0/Penicillins; 0/Proton Pumps; 26787-78-0/Amoxicillin; 81103-11-9/Clarithromycin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Helicobacter pylori-gastrin link in MALT lymphoma.
Next Document:  Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.